Ategrity Specialty Insurance Company Holdings is trading at a notable price-to-book discount compared to peers in the excess and surplus (E&S) insurance sector. While the company shows good operating leverage and profit growth from writing many policies, concerns remain about its relatively short track record and potential risks from aggressive reserve investments and related party transactions. Investors may need strong conviction in the company's future development to justify investment despite its appealing valuation.
Intellia Therapeutics saw a boost after Wedbush analyst raised its price target to $13, signaling potential upside from its current $12.64 share price. The FDA granted Priority Review to Intellia's lonvo-z treatment for Hereditary Angioedema, with a ...
Signet Jewelers reported Q2 fiscal 2027 earnings of $2.19 per share, surpassing analyst estimates of $1.69 by nearly 30%, marking its sixth consecutive quarter of earnings beats. Although revenue slightly missed expectations at $1.528 billion versus ...
UBS increased its price target for ABM Industries to $51.50 following the company's strong quarterly earnings and revenue growth. ABM reported a 4.2% revenue increase to $2.32 billion and a 19% rise in net income to $49.7 million, alongside strong ca...
Chewy reported quarterly earnings of $0.36 per share, doubling analyst estimates of $0.18, with net income rising to $80.5 million from $62 million a year ago. Quarterly revenue reached $3.33 billion, slightly above expectations, marking a 7.3% incre...
AeroVironment, a leading drone maker, is set to report its Q3 earnings on September 9, 2026, with analysts expecting EPS between $0.22 and $0.25 and revenue near $452-$456 million. The company recently secured major contracts worth over $865 million ...
